Horizon’s in-licensing and option agreement with Servier provides further commercial leverage for the company’s leading gene editing, drug combination screening and cell line expertise. We continue to believe that although the Horizon’s Products division will remain the company’s key growth driver over the next few years, Leveraged R&D could generate significant longer-term returns. We reiterate our Buy recommendation.
